BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet.
about
Chronic myeloid leukemia: reminiscences and dreamsManagement of Chronic Myeloid Leukemia Patients Resistant to Tyrosine Kinase Inhibitors TreatmentEfficacy of Dasatinib in a CML Patient in Blast Crisis with F317L Mutation: A Case Report and Literature ReviewBiomarkers for determining the prognosis in chronic myelogenous leukemiaCombating acquired resistance to tyrosine kinase inhibitors in lung cancerThe growing arsenal of ATP-competitive and allosteric inhibitors of BCR-ABLResistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: a clinical perspective and emerging treatment optionsCurrent developments in molecular monitoring in chronic myeloid leukemiaDasatinib for the treatment of chronic myeloid leukemia: patient selection and special considerationsSecondary mutations as mediators of resistance to targeted therapy in leukemiaDrug resistance missense mutations in cancer are subject to evolutionary constraintsMolecular Determinants Underlying Binding Specificities of the ABL Kinase Inhibitors: Combining Alanine Scanning of Binding Hot Spots with Network Analysis of Residue Interactions and CoevolutionBEST: Next-Generation Biomedical Entity Search Tool for Knowledge Discovery from Biomedical LiteraturemCSM-lig: quantifying the effects of mutations on protein-small molecule affinity in genetic disease and emergence of drug resistanceAHI-1: a novel signaling protein and potential therapeutic target in human leukemia and brain disorders.Tyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom?Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies.Efficacy and safety of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+ CML or relapsed/refractory Ph+ ALL: a 36-month analysis of a phase I and II study.BCR-ABL V280G Mutation, Potential Role in Imatinib Resistance: First Case ReportGenotypes of SLC22A4 and SLC22A5 regulatory loci are predictive of the response of chronic myeloid leukemia patients to imatinib treatment.Early onset hypercholesterolemia induced by the 2nd-generation tyrosine kinase inhibitor nilotinib in patients with chronic phase-chronic myeloid leukemia.Omacetaxine mepesuccinate: a new treatment option for patients with chronic myelogenous leukemia.SAHA and S116836, a novel tyrosine kinase inhibitor, synergistically induce apoptosis in imatinib-resistant chronic myelogenous leukemia cells.Chronic Myelogenous Leukemia, Version 1.2014Chronic myeloid leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Investigational Janus kinase inhibitors.A peptide antigen derived from EGFR T790M is immunogenic in non‑small cell lung cancerSuccessful nilotinib treatment in a child with chronic myeloid leukemiaStudying clonal dynamics in response to cancer therapy using high-complexity barcoding.Chronic myeloid leukemia stem cells in the era of targeted therapies: resistance, persistence and long-term dormancy.Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibitionBCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phase.Characterizing of Four Common BCR-ABL Kinase Domain Mutations (T315I, Y253H, M351T and E255K) in Iranian Chronic Myelogenous Leukemia Patients With Imatinib ResistanceIn chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants.Ponatinib as first-line treatment for patients with chronic myeloid leukaemia in chronic phase: a phase 2 study.Managing chronic myeloid leukaemia in the elderly with intermittent imatinib treatmentImplementation of management guidelines for chronic myeloid leukemia: perspectives in the United States.Structure, regulation, signaling, and targeting of abl kinases in cancer.Chronic Myeloid Leukaemia: A paradigm for malignancy or just a strange disease?Omics Screening for Pharmaceutical Efficacy and Safety in Clinical Practice
P2860
Q26748769-E3CCB82F-3E34-497F-AD7E-CEBF0DBE5BCEQ26766299-C7215BF0-24A1-436F-A494-ECD3663305DDQ26775622-DE4A5639-74AB-484F-924C-BDAEBF87FE52Q26824660-8C8959C7-00DE-461A-84A6-2E45612E5237Q26824877-54913D72-A198-409E-BF9B-664F2CE8DCBDQ26866312-DCE9546F-1253-4125-B6F8-8B5A2B5FCDF2Q27028181-85CCEE40-5974-4BDA-AD5F-6C049DC8279CQ28066148-3EEA3CDF-C247-4E9F-9887-60AF233CDCBAQ28079372-B0A17D6B-2C70-452D-ACBC-D8EB30E5A352Q28087213-52C363B3-17AF-4911-B03F-6541E284CD1AQ28537830-EE102C87-FCF7-4D5B-B49B-C3C1C3989D1AQ28548366-07F0269B-FCC7-4E03-94AB-7618F58A9003Q28552753-9CB23E8E-76C2-49E5-8794-22BC0F597229Q28831145-D7D33120-373E-4E00-9426-E80B98F98561Q30010179-BC89493E-7E9E-42CA-B038-9C0BAC556A2EQ30242015-23642FF7-3585-4770-808B-364FB65CCF7AQ30827633-0E6B55B2-9F5B-4D4D-98B6-A260DBE32149Q33399867-FFA6D0C3-1171-42E0-A157-857B8A383709Q33574738-1562CE6F-D985-47F3-86FD-602D9C236D84Q33577088-474E71EE-23F4-48B0-AA7A-211236D6237DQ33828570-BADA5D90-34AC-4388-9758-5A6D4006CE04Q33886011-9FE2D15A-D6DB-4F72-8DBD-CCB1217D9126Q33911230-EBD99C38-785D-4E44-B045-4EDC0F52DBFFQ34522810-7ACE4618-F30D-4838-A60C-C79AB413C2E7Q34642865-F62FC5A2-D1BE-4628-A2AA-DB81F771BA40Q34648724-BF6297B1-1A10-408B-9C8A-2F4AED033369Q34775850-0976D334-52C4-4B1A-A1C9-55440E9BF63FQ35225342-9A7A1165-A88F-45D0-921F-498E41C508FFQ35596310-C5B352D0-9F37-4DA0-9213-A5501F6A2AD0Q35640320-9938AA09-DB2F-4536-A807-CCED29C15346Q35760845-3C2F2C5F-660C-4232-9DAD-3DAB0035F46BQ36026747-C045ACB1-7901-4D37-9647-5B5AB5C9C230Q36088825-F06CA2B4-7677-46AA-BB1E-4DA89F569B8FQ36093137-FD982FD7-661E-4A16-A7DD-5F4084C9A5B5Q36104098-088124D7-AA73-45F4-9F00-B39ABC1B982FQ36288815-F07B8766-B2A1-4DD0-829F-2F40BA325583Q36401763-FF356018-8602-4EAC-AD1F-C33946415282Q36443429-0B0B30CA-A4D3-4CAF-9FEB-5AEC5E06E1BAQ36471739-626A3B7D-088D-4FB3-BDA0-A0F6AD7D5A96Q36477760-A4538625-F1A7-47A2-B779-0523CA423CD8
P2860
BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 11 May 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
BCR-ABL kinase domain mutation ...... ehalf of European LeukemiaNet.
@en
BCR-ABL kinase domain mutation ...... ehalf of European LeukemiaNet.
@nl
type
label
BCR-ABL kinase domain mutation ...... ehalf of European LeukemiaNet.
@en
BCR-ABL kinase domain mutation ...... ehalf of European LeukemiaNet.
@nl
prefLabel
BCR-ABL kinase domain mutation ...... ehalf of European LeukemiaNet.
@en
BCR-ABL kinase domain mutation ...... ehalf of European LeukemiaNet.
@nl
P2093
P50
P1433
P1476
BCR-ABL kinase domain mutation ...... ehalf of European LeukemiaNet.
@en
P2093
Franck E Nicolini
Franz Gruber
Martin C Müller
Nicholas C P Cross
Thomas Ernst
Thoralf Lange
P304
P356
10.1182/BLOOD-2010-12-326405
P407
P50
P577
2011-05-11T00:00:00Z